Cellectar's Iopofosine Shows Strong Results in Waldenstrom Trial

Cellectar Biosciences Q1 2026 update showcases promising progress in their radiopharma pipeline, particularly iopofosine I one thirty-one, which demonstrated impressive results in a Phase two b trial for relapsed or refractory Waldenstrom macroglobulinemia patients. The company ended the quarter with a cash balance of $8.3 million, following an oversubscribed financing round that could bring up to $140 million. They are planning to start a randomized Phase three trial and have already initiated a Phase one b trial for CLR one twenty-five in triple-negative breast cancer. With a strong pipeline and potential approval by mid-2027, Cellectar is poised to make a significant impact in oncology. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0b754f9a9e01c75a